Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 27, 2025 | = | ÷ | = | ÷ | |||||||
Feb 22, 2024 | = | ÷ | = | ÷ | |||||||
Feb 23, 2023 | = | ÷ | = | ÷ | |||||||
Feb 24, 2022 | = | ÷ | = | ÷ | |||||||
Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
Feb 28, 2019 | = | ÷ | = | ÷ | |||||||
Feb 22, 2018 | = | ÷ | = | ÷ | |||||||
Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
Feb 29, 2016 | = | ÷ | = | ÷ | |||||||
Feb 27, 2015 | = | ÷ | = | ÷ | |||||||
Feb 28, 2014 | = | ÷ | = | ÷ | |||||||
Feb 28, 2013 | = | ÷ | = | ÷ | |||||||
Feb 28, 2012 | = | ÷ | = | ÷ | |||||||
Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
Mar 1, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
- Share Price Trend
- The share price exhibited notable fluctuations over the analyzed period. Beginning at $26.26, it declined gradually to a low of $12.31 by early 2009. After this trough, the price generally trended upwards, reaching a peak of $45.96 in 2022. Subsequently, the share price experienced a decline, decreasing to $26.10 by 2025. This pattern indicates periods of volatility with phases of recovery and correction.
- Sales per Share Dynamics
- Sales per share remained relatively stable in the initial years, fluctuating around the $6 to $8 range through 2011. From 2012 onwards, there was a general upward trend, peaking at $18.01 in 2023, which represents significant growth in per-share sales. However, a reduction followed, decreasing to $11.23 by 2025. This suggests periods of strong sales growth interspersed with a recent contraction.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio demonstrated variance throughout the period. It started moderately high at 3.77 in 2006, decreasing sharply to 1.72 by 2009, coinciding with the low share price and steady sales per share. Subsequently, the ratio increased again to a peak of 4.49 in 2019, indicating that share prices were rising faster than sales per share during this time. In the last years, the ratio declined to approximately 2.32 by 2025, reflecting either a relative decrease in share prices, an increase in sales per share, or both.
- Overall Insights
- The data indicates that while sales per share experienced overall growth with some volatility, the share price was more susceptible to market fluctuations, illustrating periods of investor optimism and concern. The P/S ratio movements suggest shifts in market valuation relative to sales, with especially high valuation multiples observed around 2019 before moderating in the subsequent years. This combination of trends suggests that market sentiment and sales performance have not always moved in tandem, reflecting external factors influencing investor perception and company valuation.
Comparison to Competitors
Pfizer Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 27, 2025 | ||||||||||||
Feb 22, 2024 | ||||||||||||
Feb 23, 2023 | ||||||||||||
Feb 24, 2022 | ||||||||||||
Feb 25, 2021 | ||||||||||||
Feb 27, 2020 | ||||||||||||
Feb 28, 2019 | ||||||||||||
Feb 22, 2018 | ||||||||||||
Feb 23, 2017 | ||||||||||||
Feb 29, 2016 | ||||||||||||
Feb 27, 2015 | ||||||||||||
Feb 28, 2014 | ||||||||||||
Feb 28, 2013 | ||||||||||||
Feb 28, 2012 | ||||||||||||
Feb 28, 2011 | ||||||||||||
Feb 26, 2010 | ||||||||||||
Feb 27, 2009 | ||||||||||||
Feb 29, 2008 | ||||||||||||
Mar 1, 2007 | ||||||||||||
Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Pfizer Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Pfizer Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 27, 2025 | ||
Feb 22, 2024 | ||
Feb 23, 2023 | ||
Feb 24, 2022 | ||
Feb 25, 2021 | ||
Feb 27, 2020 | ||
Feb 28, 2019 | ||
Feb 22, 2018 | ||
Feb 23, 2017 | ||
Feb 29, 2016 | ||
Feb 27, 2015 | ||
Feb 28, 2014 | ||
Feb 28, 2013 | ||
Feb 28, 2012 | ||
Feb 28, 2011 | ||
Feb 26, 2010 | ||
Feb 27, 2009 | ||
Feb 29, 2008 | ||
Mar 1, 2007 | ||
Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Pfizer Inc. | Health Care | |
---|---|---|
Feb 27, 2025 | ||
Feb 22, 2024 | ||
Feb 23, 2023 | ||
Feb 24, 2022 | ||
Feb 25, 2021 | ||
Feb 27, 2020 | ||
Feb 28, 2019 | ||
Feb 22, 2018 | ||
Feb 23, 2017 | ||
Feb 29, 2016 | ||
Feb 27, 2015 | ||
Feb 28, 2014 | ||
Feb 28, 2013 | ||
Feb 28, 2012 | ||
Feb 28, 2011 | ||
Feb 26, 2010 | ||
Feb 27, 2009 | ||
Feb 29, 2008 | ||
Mar 1, 2007 | ||
Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).